Cytosorbents (CTSO) Receivables - Net (2011 - 2026)

Cytosorbents has reported Receivables - Net for 16 years, with the latest figure at $7.2 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net fell 6.76% year-over-year to $7.2 million; the trailing twelve-month figure through Mar 2026 stood at $7.2 million (down 6.76% YoY), and the FY2025 full-year result was $7.6 million, up 3.14% from the prior year.
• Receivables - Net for Q1 2026 stood at $7.2 million, down from $7.6 million in the prior quarter.
• The five-year high for Receivables - Net was $7.8 million in Q2 2024, with the low at $4.6 million in Q1 2022.
• Historically, Receivables - Net has averaged $6.5 million across 5 years, with a median of $6.8 million in 2024.
• Annual changes were most pronounced in 2022 — Receivables - Net slipped 10.14% — and 2023, when it soared 35.85%.
• Cytosorbents' Receivables - Net stood at $5.7 million in 2022, then increased by 6.92% to $6.1 million in 2023, then rose by 20.85% to $7.3 million in 2024, then grew by 3.14% to $7.6 million in 2025, then retreated by 5.27% to $7.2 million in 2026.
• The last three Receivables - Net figures came in at $7.2 million (Q1 2026), $7.6 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.